MedTrace Logo

Application of Desferal to Treat COVID-19

NCT04333550 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2020-05-04

No results posted yet for this study

Summary

In this study, defined cases of COVID-19 with mild, moderate or severe pneumonia will be treated with standard treatment regimens in combination with IV injection of Deferoxamine. Improvement in clinical, laboratory and radiological manifestations will be evaluated in treated patient compared to control group.

Conditions

Interventions

DRUG

Deferoxamine

Intravenous infusion of Deferoxamine

Sponsors & Collaborators

  • Kermanshah University of Medical Sciences

    lead OTHER

Principal Investigators

  • Yadollah Shakiba, MD, PhD · Regenerative Medicine Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran

  • Amir Kiani, PhD · Regenerative Medicine Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
3 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-04-30
Primary Completion
2020-09-30
Completion
2021-03-31

Countries

  • Iran

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04333550 on ClinicalTrials.gov